NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Teladoc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On July 29, 2026, Teladoc reported its financial results for the second quarter of 2026 and updated its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, compared to prior guidance in the range of $2.48 billion to $2.58 billion.  Teladoc cited “uncertainties inherent in cash pay and ongoing business model transition”.  The Company also identified various pressures facing its BetterHelp platform, including faster insurance preference, accelerated cash pay decline, and network capacity lagging demand. 

On this news, Teladoc’s stock price fell $2.60 per share, or 38.32%, to close at $6.58 per share on July 30, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980